GLP-1 Drugs and Hypoglycaemia: Who Is at Risk and How to Manage It

The hypoglycaemia story for GLP-1 drugs is simpler than for many other diabetes medications — but only for the right patient population. For T2D patients on combination therapy, it is a real clinical concern.

This article awaits medical-reviewer signoff.

Why GLP-1 monotherapy is low-risk for hypoglycaemia

The GLP-1 receptor agonist mechanism is glucose-dependent. When GLP-1 receptors are activated:

• Insulin secretion from pancreatic beta-cells increases — but only when blood glucose is elevated
• Glucagon suppression occurs — but this too attenuates when blood glucose approaches normal range

As blood glucose falls toward normal, these mechanisms automatically reduce their effect. At blood glucose below approximately 70 mg/dL (the hypoglycaemia threshold), GLP-1-mediated insulin stimulation essentially stops.

Clinical consequence: GLP-1 monotherapy in non-diabetic obesity patients does not produce hypoglycaemia from the drug mechanism. The glucose-dependent shutoff is the safety feature. Obesity patients on Wegovy or Zepbound alone are not at meaningful hypoglycaemia risk from the drug itself.

When hypoglycaemia risk appears: combination therapy in T2D

The risk emerges when a GLP-1 drug is added to:

Insulin

Insulin is not glucose-dependent — it lowers blood glucose regardless of the current level. When a GLP-1 drug is added to insulin, the GLP-1's insulin-stimulating effect adds onto the insulin's direct effect. The combined glucose-lowering can push blood glucose below the safe threshold if the insulin dose is not reduced.

Label guidance: The semaglutide and tirzepatide prescribing labels recommend:

• Consider reducing the basal insulin dose by 20% when starting a GLP-1 in patients on basal insulin with HbA1c near target
• Monitor glucose closely after starting a GLP-1 with insulin
• Patient education on hypoglycaemia recognition and management

Sulfonylureas

Sulfonylureas (glipizide, glyburide, glimepiride) stimulate insulin release in a glucose-independent manner — they cause insulin secretion regardless of blood glucose level. Combined with a GLP-1 drug, the additive insulin stimulation can cause hypoglycaemia.

Label guidance: Consider reducing the sulfonylurea dose when starting a GLP-1 drug to reduce hypoglycaemia risk.

SGLT2 inhibitors

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) lower blood glucose by blocking renal glucose reabsorption. SGLT2 inhibitors themselves have low independent hypoglycaemia risk (the mechanism is glucose-dependent in a different way). GLP-1 + SGLT2 inhibitor combinations are generally well tolerated from a hypoglycaemia perspective, without the same additive risk as insulin or sulfonylurea combinations.

Exercise and hypoglycaemia

Exercise independently lowers blood glucose — muscle glucose uptake during exercise is a primary mechanism. For T2D patients on insulin or sulfonylurea alongside a GLP-1:

• Exercise-related glucose lowering combines with the drug-related glucose lowering
• Risk of hypoglycaemia is higher during and after exercise
• Monitoring blood glucose before, during, and after exercise is appropriate
• Having fast-acting carbohydrates (glucose tablets, sports gel, fruit juice) accessible during exercise is important

Hypoglycaemia recognition and management

Symptoms:

• Shakiness, trembling
• Sweating
• Palpitations, rapid heartbeat
• Pallor, cold skin
• Hunger
• Dizziness, lightheadedness
• Confusion, difficulty concentrating
• Weakness

Severe hypoglycaemia: Loss of consciousness, seizure — requires emergency response (glucagon injection or 911 if unconscious)

The Rule of 15 (standard hypoglycaemia management):

1. Check glucose — if below 70 mg/dL and symptomatic, treat
2. Take 15–20 grams of fast-acting carbohydrates:
   • 3–4 glucose tablets
   • 4 oz (120 mL) of fruit juice or regular (not diet) soft drink
   • 1 tablespoon of honey or sugar
3. Wait 15 minutes and recheck glucose
4. If still below 70 mg/dL, repeat
5. When glucose is above 70 mg/dL, eat a small snack with protein if the next meal is more than 1 hour away

Emergency glucagon: Patients on insulin alongside a GLP-1 should have emergency glucagon available (injectable kit or nasal glucagon). Instruct family members or partners on how to use it.

Editorial note: This article awaits medical-reviewer signoff. Hypoglycaemia risk and management are clinical decisions involving the prescriber. Do not adjust insulin or other diabetes medications without prescriber guidance.